The FDA announced on July 28, 2022, that Lupin Pharmaceuticals Inc. voluntarily recalled Rifampin Capsules, USP, 150 mg due to CGMP deviations involving out-of-specification results for the MNP impurity. The recall affects 7,872 bottles distributed nationwide.
How to tell if you have it
- Brand: Lupin Pharmaceuticals
- Product: Rifampin Capsules, USP, 150 mg
- Packaging: 30 count HDPE bottles
- NDC: 68180-658-06
- Lot #: A200170
- Expiration date: December 2023
The hazard
The recall was initiated because an out-of-specification result was observed in the 1-Methyl-4-Nitroso Piperazine (MNP) impurity during manufacturing. The FDA classified this as a Class II recall.
Context
GovInfoNow's records show Lupin Pharmaceuticals Inc. has 90 other recalls on record since January 31, 2013. Recent brand recalls include the August 3, 2026 Clobetasol Cream Recall for failed content uniformity and the June 23, 2026 Glucagon Emergency Kit Recall for CGMP deviation risks. Other recent recalls of similar products include the May 14, 2026 Asclemed Duloxetine Capsules Recall, the October 22, 2025 Zydus Clomipramine Capsules Recall, and the March 27, 2026 Appco Pharma Prazosin Capsules Recall.